Explore

Stanford University Seeks Postdoctoral Researcher in Liquid Biopsy and Cancer Genomics

Stanford University Seeks Postdoctoral Researcher in Liquid Biopsy and Cancer Genomics

Stanford University's Diehn Laboratory, situated within the Stanford Cancer Institute and Department of Radiation Oncology, is actively recruiting a postdoctoral scholar. This position focuses on the intersection of liquid biopsy, cancer genomics, and computational biology. The research involves working with circulating tumor DNA (ctDNA) and cell-free RNA (cfRNA) to develop and apply methods for cancer detection, minimal residual disease assessment, treatment response prediction, and resistance characterization. The lab investigates various cancer types, with a significant emphasis on bladder, prostate, kidney, and lung cancers. The role can be bench-focused, computational, or a hybrid of both, offering flexibility based on the candidate's expertise. Funding for the lab's research is provided by the National Institute of Health, the Department of Defense, Cancer Research UK, and several foundations, ensuring robust support for the research initiatives.

Prostate Cancer Genomic Analysis Identifies Mutational Footprints Linked to Clinical Outcomes

Prostate Cancer Genomic Analysis Identifies Mutational Footprints Linked to Clinical Outcomes

A recent genomic analysis of nearly 1,000 prostate tumor samples has identified eight integrated mutational footprints (IMFs) that account for the majority of genetic alterations in prostate cancer genomes. Conducted by researchers including Joachim Weischenfeldt, PhD, from the University of Copenhagen, the study utilized whole-genome sequencing data from 959 primary prostate cancers with diverse histopathological stages and clinical outcomes. The analysis integrated multiple signature modalities, including single-base substitutions, insertion-deletions, copy number variants, and complex structural variants. These IMFs, which explain mutational processes in 85% of primary prostate cancer genomes, are primarily linked to hormone signaling, DNA replication and repair failures, and aging. The study found that four of these IMFs, present in 37% of primary tumors, were significantly associated with a shorter time to metastasis, while others predicted sensitivity to androgen receptor pathway inhibitors.

FDA Clears CU Anschutz Clinical Trial for Engineered Immune Cells Against Colorectal Cancer

FDA Clears CU Anschutz Clinical Trial for Engineered Immune Cells Against Colorectal Cancer

The U.S. Food and Drug Administration (FDA) has granted permission for a clinical trial at the University of Colorado Anschutz to test genetically engineered immune cells against advanced colorectal cancer in adults and solid cancers in pediatric patients. This experimental CAR T-cell therapy, developed by CU Anschutz researchers and manufactured at the campus's Gates Biomanufacturing Facility, is designed to target two pathways: B7-H3, a protein found on most colorectal tumors, and IL-8, which promotes tumor growth and spread. The trial aims to address the challenges of treating solid tumors, which have been more difficult to tackle with CAR T-cell therapies compared to blood cancers. The approach has shown effectiveness in animal models, and the trial is expected to begin in December.

Epigenomics Emerges as Key to Personalized Medicine and Early Disease Detection

Epigenomics Emerges as Key to Personalized Medicine and Early Disease Detection

Epigenomics, the study of gene expression without altering DNA sequences, is gaining recognition as a crucial element in achieving true personalized medicine and advancing early disease detection technologies. Unlike genomics, which examines the DNA blueprint, epigenomics focuses on the 'control panel' that determines which genes are expressed, acting as a thermostat to help cells respond to environmental conditions. Epigenetic tags, which are sensitive to environmental changes, can serve as indicators for health, disease, and toxic exposures. Aberrant DNA methylation, a key epigenomic process, has been linked to various diseases, including cancer, metabolic dysfunction, and neurodevelopmental disorders. Researchers are utilizing technologies like next-generation sequencing (NGS) and methylation microarrays to profile DNA methylation genome-wide, investigating associations between methylation patterns and phenotypes, environmental exposures, and disease.

Chronic Interferon Exposure Linked to Immunosuppression in Cancer, Salk Institute Study Reveals

Chronic Interferon Exposure Linked to Immunosuppression in Cancer, Salk Institute Study Reveals

A team at the Salk Institute has identified a novel pathway linking chronic exposure to interferon II (IFN-II) with mitochondrial dysfunction, ultimately leading to immunosuppression in cancer. Interferons, initially crucial for recruiting immune cells to fight cancer, can paradoxically become pro-cancer when exposure is prolonged. The study, published in 'Science,' explains how IFN-II causes mitochondrial genetic material (mtRNA) to exit the mitochondria. This mtRNA is then perceived by the cell as an invader, triggering the production of interferon I (IFN-I). Subsequently, IFN-II and IFN-I synergize to increase the synthesis of cyclooxygenase 2, which in turn boosts prostaglandin E2 (PGE2) production. PGE2 is a bioactive lipid known to promote immunosuppression, contributing to cancer progression and resistance to immunotherapies. This research provides foundational insights into why interferons can switch from being anti-cancer to pro-cancer agents.

Mass General Brigham Study Links Daily Sugar-Sweetened Beverage Consumption to Increased Stomach Cancer Risk

Mass General Brigham Study Links Daily Sugar-Sweetened Beverage Consumption to Increased Stomach Cancer Risk

A new study conducted by Mass General Brigham has found a significant association between the daily consumption of sugar-sweetened beverages and an increased risk of developing stomach cancer. The research, published in the journal Gastro Hep Advances, indicates that individuals who drink at least one sugar-sweetened beverage per day more than double their risk of stomach cancer compared to those who rarely consume such drinks. This extensive study analyzed data from over 100,000 participants in the Nurses’ Health Study and Health Professionals Follow-up Study, meticulously tracking diet, lifestyle, and health over several decades. The study identified 278 participants who developed stomach cancer during the follow-up period. Sugar-sweetened beverages, as defined in the study, include carbonated drinks, punch, lemonade, and sports drinks. Importantly, the study did not find a similar link with artificially sweetened beverages. This research marks the first time such an association has been demonstrated in ...

NCCN and Flatiron Health Renew Collaboration to Advance Real-World Data Research in Cancer Care

NCCN and Flatiron Health Renew Collaboration to Advance Real-World Data Research in Cancer Care

The National Comprehensive Cancer Network (NCCN) and Flatiron Health have announced the renewal of their collaboration, extending their partnership through 2028. This agreement, which originated in 2014, aims to advance real-world data (RWD) research across leading cancer centers. As part of the renewed collaboration, Flatiron Health is expanding access for NCCN Member Institutions to its AI-powered oncology intelligence platform, Flatiron Telescope. This platform enables a broader range of users to conduct research and generate insights from Flatiron's curated, de-identified oncology datasets, which span over 6 million patient journeys. The collaboration will continue to provide analytic support, educational programming, and research grants through the Flatiron Grants program, offering up to seven grants biannually to eligible subscribers.

Damon Runyon Cancer Research Foundation Awards $4.8 Million to Clinical Cancer Researchers

Damon Runyon Cancer Research Foundation Awards $4.8 Million to Clinical Cancer Researchers

The Damon Runyon Cancer Research Foundation has allocated $4.8 million to support clinical cancer researchers. This funding includes awards to six new Damon Runyon Clinical Investigators and continuation grants for three existing Clinical Investigators. Each new investigator will receive $600,000 over three years, with the foundation also offering to retire up to $100,000 of medical school debt. The continuation grants provide an additional two years of funding, totaling $400,000 each. These awards are designed to support early-career physician-scientists conducting patient-oriented cancer research at major U.S. research centers. The program aims to address financial barriers that often prevent medical doctors from pursuing research, thereby increasing the number of physicians capable of translating scientific discoveries into new cancer treatments. The funded projects cover a range of cancers, including acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), chronic lymphocytic leukemia (CLL), brea...

Advancements in Prostate Cancer Treatment Focus on Personalized Medicine and Targeted Therapies

Advancements in Prostate Cancer Treatment Focus on Personalized Medicine and Targeted Therapies

Treatment for advanced prostate cancer is undergoing significant advancements, with a growing emphasis on personalized medicine and targeted therapies. Doctors are increasingly moving away from single-medication approaches, instead opting for intensified multi-therapy regimens that can delay disease progression and improve survival for certain patients. These regimens can include single, double, triple, or quadruple therapies, tailored to the cancer's aggressiveness, spread, and patient response, without necessarily increasing side effects. Key breakthroughs include the importance of DNA genetic testing, which now extends to a panel of 150 genes beyond BRCA, allowing doctors to match specific prostate cancer variants to targeted treatments. Researchers have discovered that some prostate cancers share DNA changes with breast cancers, opening the door for treatments like PARP inhibitors, which target DNA repair pathways and are effective in up to 40% of men with advanced tumors. Additionally, improved imagin...

Alignerr Seeks Precision Medicine Data Lead for AI Training in Healthcare

Alignerr Seeks Precision Medicine Data Lead for AI Training in Healthcare

Alignerr Seeks Precision Medicine Data Lead for AI Training in Healthcare

Merck and Moderna Announce Promising mRNA Cancer Vaccine Trial Results for Melanoma

Merck and Moderna Announce Promising mRNA Cancer Vaccine Trial Results for Melanoma

Pharmaceutical companies Merck and Moderna have announced hopeful human clinical trial results for individualized mRNA vaccines designed to protect against melanoma. This development marks a significant step in cancer treatment, utilizing the same messenger RNA (mRNA) technology that was foundational to the COVID-19 vaccines. The trials combined these personalized vaccines with an FDA-approved immunotherapy drug, leading to improved recurrence-free survival rates for patients. If approved by the FDA, this would be the first mRNA cancer treatment of its kind. Dr. Elias Sayour, a pediatric oncologist and professor at the University of Florida, highlighted the potential for this technology to create an entirely new class of personalized drugs capable of making previously incurable conditions curable. The process involves taking blood and cancer cell samples from a patient, sequencing their DNA and RNA to identify tumor mutations, and then creating a customized mRNA vaccine. This vaccine instructs the body's i...

mRNA Vaccines Utilize Lipid Nanoparticles for Spike Protein Delivery, Showing High Efficacy Against COVID-19

mRNA Vaccines Utilize Lipid Nanoparticles for Spike Protein Delivery, Showing High Efficacy Against COVID-19

mRNA vaccines employ lipid nanoparticles to deliver instructions for the spike protein into host cells. Once inside, the mRNA is translated into proteins and then rapidly degraded, without altering human DNA. This mechanism was central to the development of COVID-19 mRNA vaccines, which demonstrated approximately 95% efficacy against symptomatic COVID-19 in Phase 3 data. Common short-term immune effects observed after vaccination include fatigue, myalgias, headache, and fever, which are considered expected reactogenicity rather than vaccine injury. A key misconception that mRNA changes the genome is addressed by clarifying that mRNA does not enter the nucleus of the cell. The initial authorization of these vaccines highlighted the importance of transparent communication regarding knowns, unknowns, and the rigorous safety steps undertaken during emergency authorization.